Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy

Read also

Myeloma

Myeloma treatment HDP-101 put on FDA fast track

Evotec Announces Progress

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Tylenol (paracetamol)

Tylenol (paracetamol) fights autism claims, slams proposed FDA warning label as 'unsupported' by science

Cullinan Therapeutics showcases

Cullinan Therapeutics showcases preclinical data for autoimmune drug CLN-978